Conjugated estrogens oral - Teva

Drug Profile

Conjugated estrogens oral - Teva

Alternative Names: Enjuvia; Synthetic conjugated estrogens, B - Barr Laboratories

Latest Information Update: 19 May 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Barr Laboratories
  • Developer Teva Womens Health
  • Class Estradiol congeners; Hormonal replacements; Osteoporosis therapies
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Atrophic vaginitis; Vasomotor symptoms

Most Recent Events

  • 18 May 2010 Efficacy data from a clinical trial in Vasomotor symptoms released by Teva Women's Health
  • 04 Oct 2007 Launched for Vaginal atrophy in USA (PO)
  • 30 Apr 2007 Registered as Enjuvia™ 0.9mg tablets for Vasomotor symptoms in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top